Navigation Links
Encorium Group Enters into Non-Binding Letters of Intent
Date:5/11/2009

Reiterates Going Concern Opinion to Comply with NASDAQ Marketplace Rule 4350(b)(1)(B)

WAYNE, Pa., May 11 /PRNewswire/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has entered into two non-binding letters of intent ("LOI") with respect to its U.S. business and its wholly owned European subsidiary, Encorium Oy.

The first LOI involves the sale of the assets of Encorium Group, Inc., USA, the Company's U.S. business. The Company has signed a non-binding LOI with a full-service internationally based contract research organization for an undisclosed price.

The second LOI involves the sale of the Company's wholly owned subsidiary Encorium Oy. The Company has signed a non-binding LOI with a leading full-service clinical research organization based in the United States and with operations globally.

Terms of both agreements remain confidential and the closing of each sale is subject to the completion of due diligence, execution of definitive agreements, and the fulfillment of certain closing conditions, including, with respect to the sale of Encorium Oy, Stockholder approval. Although the terms of the transactions are not yet definitive, it is not currently expected that distributions to stockholders will result in a substantial premium, if any, to the current stock price.

Dr. David Ginsberg, Encorium Group's Chief Executive Officer, commented, "Over the last several months we have been actively pursuing opportunities to enhance and maximize stockholder value. Encorium's management and Board have determined a sale
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Encorium Appoints Shahab Fatheazam to its Board of Directors
2. Encorium Announces Receipt of Letter from Nasdaq Regarding its 2008 Form 10-K Filing
3. Encorium Reports Fourth Quarter and Full Year 2008 Financial Results
4. Broad-based group of physicians calls for improvement in stroke treatment
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. CIGNA Group Insurance Shows Consumers Theres More to Life Through a New Consumer Education Toolkit
7. HIDA Calls for Scrutiny of Group Purchasing Organization Distributor Fee Structure
8. New Research Uncovers how to Build and Maintain an Effective Competitive Intelligence Group
9. AMERIGROUP to Acquire Memphis Health Plan
10. Securians Minnesota Life Continues to Climb Group Life Rankings
11. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... the groundwork for their own spread throughout the body ... tumor-welcoming signals, according to a new report by Johns ... of Nature Communications , the researchers describe animal ... signaling molecules released by breast cancer cells. These molecules ... lymph nodes to produce proteins called CCL5 and VEGF. ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... U.S. obesity epidemic is a driving force behind the rising ... Researchers looked at data from five national surveys spanning ... in diabetes over time could be explained by factors such ... adults. The investigators found that the prevalence of diabetes ...
(Date:9/2/2014)... -- A leading group of oncologists has released updated ... advanced breast cancer. HER2-negative breast tumors include ... HER2 protein, the American Society of Clinical Oncology (ASCO) ... 80 percent of women with advanced breast cancer have ... guideline, our aim is to improve both the length ...
(Date:9/2/2014)... latest research on sleep apnea, tonsillectomies, hearing loss, ... will be presented in Orlando, FL, September 21-24, ... of the American Academy of OtolaryngologyHead and Neck ... ear, nose, throat, head and neck physicians in ... be presented were released today, and are available ...
(Date:9/2/2014)... September 02, 2014 The first ... Pinnacle hip implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon ... the U.S. District Court, Northern District of Texas, ... Johnson & Johnson and its DePuy Orthopaedics unit ... all-metal hip caused recipients to suffer serious and ...
Breaking Medicine News(10 mins):Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4
... leverage Risk MonitorPro, (R) and Feedback ... patient feedback and adverse events,CAMBRIDGE, MA, Jan. 13 ... quality and safety software, announced today that Woman,s Hospital ... and quality of care initiatives. , Named by Modern ...
... Straight Wire Seminars(TM) Celebrates 3 Decades of Orthodontic ... Straight Wire Seminars , Inc., a leading provider ... 30th anniversary starting this month, January 2009. ... milestone by offering a wide array of courses ...
... to enter Animal Health Rapid Diagnostics Market with a ... 13 Abaxis, Inc. (Nasdaq: ABAX ), ... for both the medical and veterinary markets, announced today ... for the manufacturing of a Canine Heartworm Lateral Flow ...
... Merck Serono and Apitope to Collaborate on Development ... the Treatment of Multiple Sclerosis (MS)GENEVA, Jan. 13 ... Darmstadt, Germany, announced today the signature of a ... (Bristol) Ltd., a wholly owned subsidiary of Apitope ...
... The National Eczema Association (NEA) awarded its Seal ... Theraplex Clear Lotion .The NEA Seal of Acceptance is ... program, which is intended to improve the quality of ... skin. "These products met our criteria for having no ...
... and Web 2.0 as Top Security Concerns and Steps Organizations Need to ... ... Ariz. (PRWEB) January 13, 2009 -- What will be the biggest threats ... 24 months? Cybercrime, data breaches , Web 2.0 and outsourcing were ...
Cached Medicine News:Health News:Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting 2Health News:Don't Trust Any Continuing Education Provider Under 30 2Health News:Don't Trust Any Continuing Education Provider Under 30 3Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 2Health News:ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 2Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 3Health News:Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis 4Health News:National Eczema Association Anoints Theraplex Products with Seal of Acceptance 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 2Health News:Lumension Security Webinar Focuses on Security Mega Trends and Emerging Threats in 2009 3
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... 2, 2014 , ... provide insight into treatment and outcomes of patients ... --   Data from nearly 12,500 ... the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic ... for atrial fibrillation (AF) patients remain sub-optimal despite ...
(Date:9/2/2014)... -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... at the Morgan Stanley Global Healthcare Conference in ... September 9, 2014 , Presentation time: 5:15 p.m. ET ... of this presentation will be available at http://ir.avanir.com . ... Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... is the principal hormone responsible for the control ... the b-cells of the islets of Langerhans as ... C-peptide and insulin. Both are secreted in ... mature insulin molecule is comprised of two polypeptide ...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: